(News Bulletin 247) – Bayer AG and its wholly-owned subsidiary BlueRock Therapeutics LP today presented details of positive Phase I trial data for bemdaneprocel (BRT-DA01), an investigational cell-derived therapy strains to treat Parkinson’s disease.
The study achieved the primary objective of demonstrating safety and tolerability in all 12 participants with no serious adverse events (SAEs) related to bemdaneprocel reported for one year.
“The data from this open-label, phase I study is extremely encouraging,” said Claire Henchcliffe, chair of the department of neurology at the UCI School of Medicine at the University of California at Irvine and one of the principal investigators of the study.
“Although this is a small, open-label study, achieving the primary study objective of safety and tolerability as well as the first observed improvements in clinical outcomes is a big step forward. We now hope that these trends will continue and translate into meaningful benefits for people with Parkinson’s disease in controlled clinical trials. ‘
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
